Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01Aditya Bardia, Jennifer Friedmann, Michelino De Laurentiis et al.|Journal of Clinical Oncology|2024Cited by 163
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trialNadia Harbeck, Marion van Mackelenbergh, Eva Ciruelos et al.|Nature Medicine|2024Cited by 8